Cleveland, OH – October 15, 2006 – Qualtran, LLC. – a contract research organization (CRO) – announced today the signing of a new clinical trial for Arrhythmia drug with Chantest Inc., USA

ChanTest was recently ranked as the “most trusted fee-for-service provider” for ion channel safety screening by John Comley’s 2006 HTstec Ion Channel Trends Survey. The survey polls lab personnel from large pharma, medium, and small pharma, universities and government labs that outsource ion channel safety studies.

This 78 patient drug trial will be conducted in India in 2007 at Escorts Hospital and Sir Ganga Ram Hospital. This is a second phase study with the first phase completed in USA. “We’re excited about the new drug trial and its prospects to treat arrhythmia” said Sunil Sawhney, Head of Indian Operations of Qualtran.

About Qualtran, LLC.

Qualtran is a full-service contract research organization (CRO) specializing in medical devices, IVDs (in vitro diagnostics) and drug trials. Since its inception in 2003, Qualtran has served more than 15 device and drug companies worldwide in the areas of clinical management, regulatory affairs and compliance/quality systems. For more information, see www.qualtran.com or call +1.216.378.7558.

For more information, contact:
Sid Kler
Business Development
011-91-9810270955
[email protected]